Syndax Pharmaceuticals, Inc. (SNDX)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Syndax Pharmaceuticals, Inc. (SNDX)
Company Performance

Current Price

as of Oct 16, 2024

$19.89

P/E Ratio

N/A

Market Cap

$1.69B

Description

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Metrics

Overview

  • HQWaltham, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerSNDX
  • Price$19.89+0.71%

Trading Information

  • Market Cap$1.69B
  • Float93.36%
  • Average Daily Volume (1m)902,245
  • Average Daily Volume (3m)973,046
  • EPS-$3.38

Company

  • Revenue$3.50M
  • Rev Growth (1yr)N/A
  • Net Income-$68.06M
  • Gross MarginN/A
  • EBITDA Margin-2,120.37%
  • EBITDA-$74.21M
  • EV$1.33B
  • EV/Revenue379.06
  • P/EN/A
  • P/S484.61
  • P/B3.89
Documents
SEC Filings
8-K (2024-08-01)
8-K (2024-05-15)
8-K (2024-05-08)
8-K (2024-03-18)
8-K (2024-02-27)
8-K (2023-12-20)
8-K (2023-12-15)
8-K (2023-12-12)
8-K (2023-11-02)
8-K (2023-10-02)
8-K (2023-08-03)
8-K (2023-07-24)
8-K (2023-05-26)
8-K (2023-05-18)
8-K (2023-05-08)
8-K (2023-03-30)
8-K (2023-02-28)
8-K (2023-02-08)
10-Q (2024-08-01)
10-Q (2024-05-08)
10-Q (2023-11-02)
10-Q (2023-08-03)
10-Q (2023-05-08)
10-K (2024-02-27)
10-K (2023-02-28)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-02)
Earnings Report (2023-08-05)
Factset Street Account
Syndax to present updated data supporting clinical profile of Revumenib in genetically-defined acute leukemias at ASH ($13.92, 0.00) (2023-11-02T13:04:51Z)
Syndax to initiate NDA Submission of Revumenib in relapsed/refractory KMT2Ar acute leukemia under FDA's Real-Time Oncology Review Program ($11.39, 0.00) (2023-10-24T11:03:52Z)
Syndax Pharmaceuticals reports Q3 EPS ($0.73) vs FactSet ($0.79) [11 est, ($0.91)-(0.67)] ($14.78, 0.00) (2023-11-02T20:35:22Z)
Syndax Pharmaceuticals initiated buy at BofA ($11.72, 0.00) (2023-10-25T12:08:55Z)
StreetAccount Earnings Call Q&A Summary: Syndax Pharmaceuticals Q3 (2023-11-03T11:46:38Z)
Follow-up: Syndax announces AUGMENT-101 trial of revumenib in R/R KMT2Ar acute leukemia meets primary endpoint, stopped early for efficacy ($14.52, 0.00) (2023-10-02T11:04:43Z)